Business
Hemostemix Provides a Clinical Trial Update and Announces the Release and Filing of 2020 Year-end Audited Financial Statements and Management Discussion and Analysis
Calgary, Alberta--(Newsfile Corp. - April 30, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF)...
About this update from Hemostemix Inc
[{"type":"text","content":"Hemostemix Provides a Clinical Trial Update and Announces the Release and Filing of 2020 Year-end Audited Financial Statements and Management Discussion and AnalysisCalgary, Alberta--(Newsfile Corp. - April 30, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ‎‎(FSE: 2VF0) (\"Hemostemix\" or the \"Company\") is pleased to announce that, with the last patient follow up completed in April, the Company is now focusing its efforts on completing the key areas of the trial including, but not limited to, data entry, source document verification, data base query management and validation as more fully described below, biostatistical analyses and final reporting documentation. This process is expected to take approximately three months.The Company has contracted a clinical data management services company to provide Hemostemix with clinical trial data base management services, including data base management plan adherence, data base edit checks, data base query management, data base integration and validation, data base reconciliations by events, data base analysis readiness reporting, data base hard lock, and data base closeout and delivery. Hemostemix is continuing with the data entry and source document verifications. As announced on April 23, the 65th (final) subject has completed their last follow-up visit and the Company has contracted two additional clinical research associates to assist with the completion of the source document verification process. Hemostemix filed on SEDAR its audited annual financial statements for the period ending December 31, 2020, with a comparison to the year earlier period, including the notes related thereto and also including the management discussion and analysis (MD&A).ABOUT HEMOSTEMIX Hemostemix is a publicly traded autologous stem cell therapy company. A winner of the World Economic Forum Technology Pioneer Award, the Company developed and is commercializing its lead product ACP-01 for the treatment of CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and other conditions of ischemia. ACP-01 has been used to treat over 500 patients, and it is the subject of a randomized, placebo-controlled, double blind trial of its safety and efficacy in patients with advanced critical limb ischemia who have exhausted all other options to save their limb from amputation. On Octob...